These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 9484869

  • 1. Antibacterial activity of grepafloxacin.
    Wiedemann B, Heisig P.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():19-25. PubMed ID: 9484869
    [Abstract] [Full Text] [Related]

  • 2. Grepafloxacin.
    Wagstaff AJ, Balfour JA.
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [Abstract] [Full Text] [Related]

  • 3. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL, Fuchs PC.
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [Abstract] [Full Text] [Related]

  • 4. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R, Andrews JM.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
    [Abstract] [Full Text] [Related]

  • 5. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract] [Full Text] [Related]

  • 6. Safety profile of grepafloxacin compared with other fluoroquinolones.
    Stahlmann R, Schwabe R.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():83-92. PubMed ID: 9484877
    [Abstract] [Full Text] [Related]

  • 7. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997].
    Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
    Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():45-57. PubMed ID: 9484873
    [Abstract] [Full Text] [Related]

  • 9. Grepafloxacin--focus on respiratory infections.
    Geddes AM.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():1-4. PubMed ID: 9484866
    [No Abstract] [Full Text] [Related]

  • 10. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
    Goldstein EJ.
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S25-30. PubMed ID: 8953103
    [Abstract] [Full Text] [Related]

  • 11. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H, Vogel F, Elies W.
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [Abstract] [Full Text] [Related]

  • 12. In vitro antibacterial activity and pharmacodynamics of new quinolones.
    Dalhoff A, Schmitz FJ.
    Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416
    [Abstract] [Full Text] [Related]

  • 13. Quinolone activity against anaerobes.
    Appelbaum PC.
    Drugs; 1999 Apr; 58 Suppl 2():60-4. PubMed ID: 10553708
    [Abstract] [Full Text] [Related]

  • 14. New fluoroquinolone antibiotics.
    Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769
    [Abstract] [Full Text] [Related]

  • 15. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE, Cranfield R, Breisch S, Pettit R.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():63-72. PubMed ID: 9484875
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y, Ozaki M, Matsuda M, Honmura T, Nishimura I, Yamaguchi R, Adachi T, Okawa Y, Nishino T.
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [Abstract] [Full Text] [Related]

  • 17. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
    Ridgway GL, Salman H, Robbins MJ, Dencer C, Felmingham D.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
    [Abstract] [Full Text] [Related]

  • 18. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
    Hosaka M, Kinoshita S, Toyama A, Otsuki M, Nishino T.
    J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459
    [Abstract] [Full Text] [Related]

  • 19. Pneumococcal resistance in the UK.
    Goldsmith CE, Moore JE, Murphy PG.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():11-8. PubMed ID: 9484868
    [Abstract] [Full Text] [Related]

  • 20. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
    O'Doherty B, Dutchman DA, Pettit R, Maroli A.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.